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LOCAL MINOCYCLINE TO REDUCE FUTURE INFLAMMATION AND BONE LOSS IN PERIODONTAL 
MAINTENANCE PATIENTS 
Jeffery S. Jensen, D.D.S., M.S. 
University of Nebraska, 2016 
Advisor: Richard A. Reinhardt, D.D.S., Ph.D. 
The objectives of this study were to compare the effect of SRP+MM versus SRP alone on 
inflammatory cytokines, interleukin (IL)-1β and IL-1 receptor antagonist (ra), found in gingival 
crevicular fluid (GCF) and saliva, and correlate IL-1 values with  clinical outcomes over a 2-year 
period of PMT. Fifty-five patients with an initial posterior pocket ≥5 mm and history of bleeding 
on probing (BOP) were randomized to test (SRP+MM, n=27) and control (SRP, n=28) groups. 
Clinical measurements and GCF samples were done at baseline and 24 months. SRP+MM or SRP 
were provided at 6-month intervals. IL-1β and IL-1ra were measured in GCF and saliva (24 
months). A total of 48 patients completed the study (SRP+MM, n=23; SRP, n=25). Groups were 
compared using t-test, Wilcoxon test, and Spearman correlations. There was no significant 
difference or change in IL-1 or IL-1β/IL-1ra ratios levels between groups after 24 months. BOP 
level decreased significantly in both groups (SRP+MM=56%, SRP=45%). Bone loss was not 
significantly altered in either group. Both groups showed significant improvements in probing 
depth (p=0.001) and clinical attachment level (p=0.001). Baseline GCF IL-1β was correlated with 
bone loss at 24 months and salivary IL-1β was correlated with increase in probing depth at 24 
months (r=0.34, p≤0.03). The addition of MM to SRP during PMT did not significantly affect IL-1 
levels or clinical parameters.  
iv 
 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS………………………………………………………………………………………………………………. i 
ABSTRACT…………………………………………………………………………………………………………………………………. iii 
TABLE OF CONTENTS………………………………………………………………………………………………………………… iv 
LIST OF FIGURES……………………………………………………………………………………………………………………….…v 
LIST OF TABLES…………….………………………………………………………………………………………………………….…vi 
LIST OF ABBREVIATIONS…………………………………………………………………………………………………………….vii 
CHAPTER 1: INTRODUCTION……………………………………………..………………………………………………………. 1 
CHAPTER 2: LITERATURE REVIEW: PERIODONTITIS……..………………………………………………………………3 
CHAPTER 3: LITERATURE REVIEW: LOCAL DELIVERY OF MINOCYCLINE…………………..…………………..6 
CHAPTER 4: LITERATURE REVIEW: INTERLEUKEN-1β AND INTERLEUKIN-1ra……………………………..10 
CHAPTER 5: MATERIALS AND METHODS 
 Patient Population and Study Design…………..……………………………………………………………….15 
 Data Collection and Treatment Protocol……………………………………………………………………….17 
 Analysis of GCF and Salivary Samples……………………………………………………………………………19 
 Statistical Analyses……………………………………………………………………………………………………….22 
CHAPTER 6: RESULTS 
 Patient Characteristics………………………………………………………………………………………………….24 
 Inflammatory Biomarker Outcomes…..………………………………..……………………………………….24 
 Clinical Outcomes…………………………………………………………………………………………………………26 
CHAPTER 7: DISCUSSION……………..……………………………………………………………………………………………29 
CHAPTER 8: CONCLUSIONS……………………………………………..………………………………………………………..35 
BIBLIOGRAPHY………………………………………………………………………………………………………………………….36 
Appendix A: Raw Clinical Data…………………………………………………………………………………………………..45 
v 
 
LIST OF FIGURES 
Figure 1: Study design flow chart………………………………………………………………………………………………16 
Figure 2: Levels of IL-1β at baseline and 24 months (mean ± standard deviation)…………………….25 
Figure 3: Mean GCF IL-1β/IL-1ra ratio at baseline and 24 months…………………………………………….25 
Figure 4: Clinical measurements at baseline and 24 months (mean ± standard deviation)………..26 
Figure 5: Percent bleeding on probing at baseline and 24 months…………………………………………….27 




LIST OF TABLES 
Table 1: Patient characteristics across treatment groups…………………………………………………….……24  
vii 
 
LIST OF ABBREVIATIONS 
BOP  bleeding on probing 
CAL  clinical attachment level 
ELISA  enzyme-linked immunosorbent assay 
GCF  gingival crevicular fluid 
IBL  interproximal bone loss 
IL-1β  interleukin-1 beta 
IL-1ra  interleukin-1 receptor antagonist 
MM  locally-delivered minocycline microspheres 
PD  probing depth 
PMT  periodontal maintenance therapy (control) 
REC  gingival recession 




CHAPTER 1: INTRODUCTION 
 Periodontitis is an inflammatory disease affecting the supporting structures of the 
dentition. Both the hard and soft tissues of the periodontium are affected by the disease (AAP 
Parameters of Care 2000). The periodontium consists of several different tissues, including: 
cementum, alveolar bone, and the periodontal ligament. Periodontal disease affects up to half 
of the population of the United States over the age of 30; a figure much larger than originally 
estimated (Eke et al. 2015). Aging also appears to play a role in the decrease of clinical 
attachment levels and prevalence of the disease with a higher rate of occurrence in males (Eke 
et al. 2015).  
 Treatment of periodontitis with debridement of bacterial biofilm, removal of calculus 
and contaminated cementum through scaling and root planing (SRP) and/or surgical treatment 
of periodontal soft tissue and bone has been shown to be relatively successful with resolution of 
inflammation and improvement of clinical parameters (Kaldahl et al. 1996a, Becker et al. 2001, 
Mialoa et al. 2015). When a patient is determined to be stable following non-surgical and/or 
surgical therapy, they are placed into a periodontal maintenance therapy (PMT) schedule. 
Periodontal pockets that continue to show bleeding on probing (BOP) are indicative of 
continued inflammation (Amato et al. 1986) and presence of bacteria (Wilson et al. 2008). If 
recurrence of disease is noted during PMT, treatment with additional SRP may be prescribed 
and has been shown to be effective (Kaldahl et al. 1996b). 
 Like any other medical treatment, not all patients respond in the same way to 
periodontal treatment. In light of these varied responses, adjunct therapies to SRP have been 
developed and employed. These adjuncts include systemic antibiotics (Sgolastra et al. 2014), 
local delivery of antibiotics (Kinane & Radvar 1999), subgingival irrigation (Jolkovsky et al. 1990), 
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and lasers (Cobb 2006). Each of these therapies has been used with varying degrees of success 
and efficacy. Adjunct periodontal therapies aim to reduce the microbial and inflammatory load 
to a level where successful healing can occur. Local administration of minocycline microspheres 
(MM) is a technique widely used. Evidence for use of minocycline in conjunction with SRP exists 





CHAPTER 2: LITERATURE REVIEW: PERIODONTITIS 
Periodontitis is a disease affecting the supporting tissues of the dentition. A patient 
presenting with periodontitis may have manifestations of gingival erythema, discomfort, 
increased amount of gingival crevicular fluid (GCF), increase probing depths (PD), increased loss 
of clinical attachment level (CAL), tooth mobility, bleeding on probing (BOP), suppuration, 
abscesses, and gingival recession (REC). Treatment of the disease is imperative because failure 
to do so may result increased loss of attachment and eventual tooth loss (AAP Position Paper 
1999). 
Bacterial plaque and calculus have been identified as the main etiology of chronic 
periodontitis (Socransky & Haffajee 1992). However, the mere presence of pathogens does not 
appear to be sufficient for progression of the disease. Disease may occur when the pathogen is 
present and it is of a virulent clonal type, it possesses the chromosomal and extra-chromosomal 
genetic factors to initiate disease, the host is susceptible to the pathogen, the pathogen is 
present in numbers sufficient to exceed the threshold for the host, the pathogen is located in 
the right place, other bacteria species foster or do not hinder the progress of the disease, and 
the local environment is conducive to the expression of the species’ virulence properties 
(Socransky & Haffajee 1992). Host susceptibility plays a vital role in the progression of 
periodontal disease. Genetic factors such as neutrophil dysfunction (Van Dyke et al. 1985), 
neutrophil hyperactivity (Matthews et al. 2007), and IL-1 polymorphism (Kornman et al. 1997) 
have been suggested as possible genetic factors contributing to periodontal disease progression. 
 When treating periodontal disease, a clinician attempts to resolve inflammation, 
prevent progression of periodontal destruction, and restore the patient to comfort and function. 
These goals may be achieved through different therapy, including non-surgical periodontal 
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therapy, surgical therapy, or a combination of both.  These therapies aim to disrupt the bacterial 
biofilm, reduce microbial load, and minimize future recolonization. Outcomes of this treatment 
are measured using PD, BOP, PI, and gain in CAL. (Haffajee et al. 1997) 
 When performing non-surgical periodontal therapy, teeth are debrided through scaling 
and root planing. Scaling and root planing are normally done using hand instruments and/or 
ultrasonic scalers. During instrumentation of the teeth, plaque and calculus are removed, 
subgingival bacterial load is reduced (Socransky et al. 2013), and the roots are detoxified 
(Nishimine & O’Leary 1979). Scaling and root planing has long been held up as the “gold 
standard” of periodontal treatment (Cobb 2002). Following scaling and root planing, one can 
expect to see improvements in periodontal health when measuring PD, BOP, PI, and CAL 
(Kaldahl et al. 1996a, Becker et al. 2001, Mialoa et al. 2015). Other factors may be found to 
influence periodontal disease, such as: occlusal trauma, iatrogenic restorations (Jeffcoat 1980), 
tooth crowding (Bollen 2008), and smoking (Albandar 2000). In addition to non-surgical therapy, 
some cases of periodontal disease may need surgical therapy. 
 Following non-surgical and/or surgical therapy of periodontitis, patients that are 
deemed to be stable by their clinician are placed into PMT. PMT has been shown to be critical to 
long-term success (Nyman et al. 1975, Ramfjord 1982, Becker et al. 1984a, Becker et al. 1984b). 
Evidence is present that patients who refuse to follow-up with periodontal maintenance return 
to a diseased state (Axelsson & Lindhe 1981, Becker et al 1984a, Becker et al 1984b). The goals 
of periodontal maintenance include: 1) prevention or minimization of recurrence of disease 
progression in patients who were previously treated for periodontitis, 2) prevention or 
reduction of the incidence of tooth or implant loss by monitoring the dentition, and 3) to 
increase the probability of locating and treating other conditions or diseases found within the 
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oral cavity in a timely manner (Cohen 2003). During each PMT appointment, conditions of the 
periodontium are measured and evaluated, daily home care is reviewed and reinforced, and 
periodontal treatment is performed as needed (Cohen 2003). Sites that have residual signs of 
inflammation after and during PMT have been shown to be more likely to progress and deserve 
additional treatment (Claffey et al. 1990). PMT is generally carried out at 3-4 month intervals 
(Nyman et al. 1975, Schallhorn & Snider 1981).   
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CHAPTER 3: LITERATURE REVIEW: LOCAL DELIVERY OF MINOCYCLINE 
 Minocycline is a broad-spectrum antibiotic in the tetracycline family and has a 
bacteriostatic effect. In addition to the antibacterial effects, minocycline also appears to exert 
an anti-inflammatory effect in the body. Minocycline has been shown to inhibit the activity of 
matrix metalloproteinases, inducible nitric oxide synthase, and cyclooxygenase-2 (Chen et al. 
2000; Yrjänheikki et al. 1999). IL-1β and tumor necrosis factor α (TNF-α) production are also 
impaired by minocycline (Suk 2004). Minocycline also has been shown to inhibit the 
inflammatory response of monocytes challenged by LPS (Pang et al. 2012) and the formation of 
osteoclasts (Holmes et al. 2004). Minocycline’s combined anti-bacterial and anti-inflammatory 
effects make the drug an appealing therapeutic option in the treatment of periodontal disease. 
 Systemic antibiotics have been utilized in the treatment of periodontitis; however, the 
widespread use of them has been discouraged due to the possibility of developing resistant 
organisms. The development of locally delivered antibiotics has come about in hopes of avoiding 
the undesirable effects of systemic antibiotic administration. To be clinically effective, locally 
delivered antibiotics must fulfill several criteria. These therapies must reach the targeted site of 
action, remain at an effective concentration, and last for an adequate period of time (da Rocha 
et al. 2015). 
 Minocycline often is used as an adjunct to SRP through a locally-delivered mechanism. 
Minocycline is microencapsulated in polyglycolide-co-dl lactide, a bioabsorbable polymer. The 
encapsulated minocycline is then administered into the periodontal pocket in a powder form. 
Immediately following contact with moisture, the polymer begins to hydrolyze and release the 
minocycline. Administration of the minocycline microspheres results in a localized, sustained 
release of the antibiotic at concentrations of 340 µg per ml in GCF at 14 days (Williams et al. 
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2001). These concentrations are much higher than the minimum inhibitory concentrations for 
periodontal pathogens, normally thought to be 1-2 µg per ml (Hagiwara et al. 1998). 
 Several studies have investigated the application of minocycline microspheres during 
initial SRP. Williams et al. (2001) conducted a multi-center clinical trial investigating the efficacy 
and safety of locally administered minocycline microspheres. The study included 748 patients 
diagnosed with moderate to severe periodontitis randomized into three groups: SRP alone, SRP 
plus vehicle, and SRP plus minocycline microspheres. The authors reported that SRP plus 
minocycline microspheres provided more probing depth reduction when compared to SRP alone 
and SRP plus vehicle. This difference was statistically significant at 1 month and was maintained 
throughout the 9 months of follow-up. Several additional studies have shown that when used in 
adjunct to initial SRP, application of MM has resulted in improved clinical parameters (Paquette 
et al. 2004; Lessem and Hanlon 2004). 
 Oringer tested the ability of minocycline microspheres to effect markers of bone 
resorption. GCF samples were obtained at baseline, 1, 3, and 6 months and clinical 
measurements were recorded. Pyridinoline cross-linked carboxy-terminal telopeptide of type I 
collagen (ICTP), a bone-specific degradation product, and IL-1 were measured from GCF 
samples. Patients also received SRP in addition to MM or a vehicle control. Authors determined 
that GCF levels of ICTP and IL-1 were significantly reduced in patients receiving MM along with 
SRP (Oringer et al. 2002). 
 Goodson et al. (2007) investigated the antimicrobial effects of minocycline microspheres 
when used as an adjunct to SRP. Specifically, the authors looked at the effects of MM on the 
levels of red-complex bacteria: Porphyromonas gingivalis, Tannerella forsythia, and Treponema 
denticola. Test and control sites were sampled at baseline and 30 days. The study concluded 
8 
 
that levels of red complex bacteria were significantly more decreased in test sites than control 
sites. Clinical parameters also showed a significant improvement in the test group when 
compared to the control group (PD, CAL, BOP). Additional studies have also reported a reduction 
in red complex bacteria when using MM in conjunction with SRP (Grossi 2007; Bland et al. 
2010). 
 Currently, minocycline microspheres are approved for placement in inflamed 
periodontal pockets in conjunction with initial SRP therapy. However, MM is commonly used to 
treat residual inflamed periodontal pockets following active therapy. A small number of 
investigations have been completed observing the effect of MM in patients undergoing PMT. 
 Meinberg et al. (2002) studied the difference in clinical parameters between 
conventional periodontal maintenance and SRP with MM. The authors concluded that SRP and 
MM resulted in PD reduction and less frequent radiographic bone loss height than in 
conventional periodontal maintenance. MM was applied at baseline, 1, 3, and 6 month 
appointments following SRP at the baseline appointment only. Control patients received 
conventional PMT at 3 month intervals for 1 year. 
An additional study, van Steenberghe et al. (1999), evaluated the clinical and 
microbiological outcomes of repeated application of minocycline gel subgingivally. SRP was 
done at baseline, 6, and 12 months. Minocycline gel was applied at baseline, 2 weeks, 1, 3, 6, 9, 
and 12 months. The authors concluded that repeated application of subgingival minocycline gel 
resulted in improvement in both clinical and microbiologic variables over 15-months when 
compared to SRP alone. 
Long-term studies involving the measurement of clinical parameters and inflammatory 
biomarkers during PMT appear to be lacking in the literature. This investigation attempts to 
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determine whether repeated application of MM at 6-month intervals along with PMT will 
improve clinical parameters and decrease the level of inflammatory biomarkers when compared 
with 6-month PMT alone over a 2 year period.  
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CHAPTER 4: LITERATURE REVIEW: INTERLEUKEN-1β AND INTERLEUKIN-1ra 
 Interleukin-1β is a pro-inflammatory cytokine released during the inflammatory 
response, such as periodontitis, due to the presence of bacteria (Ishihara et al. 1997, Cochran 
2008). IL-1β is a glucoprotein of 17 kDa released primarily from macrophages and monocytes 
(Mergenhagen 1984, Matsuki et al. 1992). However, IL-1β may be released from a myriad of 
different types of cells, including: fibroblasts, dendritic cells, Langerhans cells, B cells, 
endothelial cells, neutrophils, epithelial cells, and bone cells (Oppenheim et al. 1986, Horowitz 
1993). IL-1β binds to interleukin-1 receptors on the cell membranes of the target cell. The 
production of IL-1β may be stimulated by various means, such as: microorganisms, microbial 
products, inflammatory agents, or antigens (Preiss & Meyle 1994). The pro-inflammatory effects 
of IL-1β are many. Some of these effects include: stimulation of T-lymphocytes and lymphokine 
production (Mizel 1987), proliferation of B-lymphocytes and antibody production (Chiplunkar et 
al. 1986), proliferation of fibroblasts, stimulation of prostaglandin release, enhancement of 
neutrophil chemotaxis and activation (Sauder et al. 1984), and release of metalloproteinases 
(Dinarello 1991). Perhaps most importantly in periodontal disease, IL-1β promotes osteoclast 
formation and is a major factor in the induction of bone demineralization (Dewhirst et al. 1985). 
As such, IL-1β is a mediator of tissue destruction seen in the course of periodontal disease (Page 
et al. 1997). Levels of IL-1β have been shown to be higher in gingival tissue involved in active 
periodontal sites compared to healthy periodontal sites (Stashenko 1991). 
 IL-1β is measured in the oral cavity in different ways, including the collection of GCF and 
saliva. IL-1β has been shown to be detectable in GCF samples. Masada et al. (1990) identified IL-
1β in the GCF in 15 of 15 patients with untreated periodontitis. Kinane et al. (1992) were able to 
detect IL-1 in the GCF of 12 of 12 patients with experimental gingivitis. Gursoy et al. (2009) were 
able to detect IL-1β in the saliva of 165 of 165 patients regardless of their periodontal status. 
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 When evaluating IL-1β in the GCF, the investigator may use different means of 
measurement, such as concentrations of IL-1β or the total amount of IL-1β in a timed sample. 
Gilowski et al. (2014) found that reporting on the concentration of IL-1 levels could be 
misleading biochemically. The total amount of IL-1 in a sample produced a more reliable result. 
This is due to the impact of small volumes in the denominator (GCF) causing fluctuations in 
concentrations. Lamster et al. (1986) reported that due to the small amount of GCF collected in 
each sample and the variability of sample size between individuals, using the total amount of 
cytokine present is more appropriate for reporting GCF data. Wei et al. (2004) were unable to 
show any significant correlation between clinical parameters and concentration of IL-1β, but 
significance was shown when using total amount of IL-1. Engebretson et al. (2002) found that 
both concentrations of IL-1 and total amount of IL-1 differed between groups with different 
severity of disease. However, the total amount of IL-1 had more pronounced differences than 
the concentration difference between groups.  
Ishihara et al. (1997) found that as the severity of periodontal disease increased the 
levels of IL-1β also increased. IL-1β was not detected in periodontally healthy subjects.  In 
diseased subjects, the IL-1β level correlated with bone loss. Engebretson et al. (2002) showed 
that total IL-1β in GCF correlated with severity of PD and CAL in patients with mild, moderate, or 
severe periodontitis. Also noted was the fact that patients with severe periodontitis exhibited an 
almost 2 fold increase in IL-1β in shallow PD compared to patients with mild or moderate 
periodontitis. The authors suggest that IL-1β expression in the GCF is a host trait, and not simply 
due to clinical parameters at the site. Gamonal et al. (2000) found that the amount of crevicular 
IL-1β was associated with periodontal status in 18 patients. IL-1β was detected at higher 
amounts in sites deemed active compared to sites deemed inactive.  These findings suggest that 
total IL-1β may be a valuable marker in the GCF to determine the inflammatory activity in 
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periodontal tissue. Sexton et al. (2011) found that in total IL-1β in saliva correlated with 
periodontal disease severity in 33 patients. 
 SRP has repeatedly been shown to improve clinical signs of inflammation and reduce IL-
1β levels in periodontally diseased areas (Engebretson et al. 1999, Gamonal et al. 2000, 
Engebretson et al. 2002, Konopka et al. 2012). The reduction in IL-1β levels may last up to 24 
weeks following SRP before returning to comparative baseline levels (Engebretson et al. 2002). 
Sexton et al. (2011) showed that IL-1β was reduced in patients receiving SRP. Patients receiving 
oral hygiene instructions only did not show the same decrease in IL-1β levels. 
 Following initial therapy, patients begin receiving PMT. Pockets exhibiting continued 
inflammation in the form of BOP are of interest to the clinician due to the continuation of the 
disease process. IL-1β levels have been shown to correspond to disease activity during PMT. 
Reinhardt et al. (2010) investigated the relationship between IL-1β levels and attachment and 
bone loss in periodontal maintenance patients. The patient population consisted of 
postmenopausal women with moderate to advanced periodontitis. Patients receiving PMT who 
showed an increase in IL-1β levels from the previous year’s visit were found to be twice as likely 
to experience disease progression the following year. Kinney et al. (2014) showed in a 
longitudinal study that patients that were considered as having progressive periodontal disease 
showed a higher level of GCF IL-1β when compared to stable periodontal patients. These results 
suggest that GCF IL-1β may provide a legitimate measurement of disease activity in a 
periodontally involved site. 
 IL-1 receptor antagonist (ra) is a member of the IL-1 family. The function of IL-1ra 
consists of binding to IL-1 receptors and antagonizing the effects of IL-1β. IL-1ra binds to 
receptors with nearly the same avidity as IL-1β (Arend 2002). When IL-1ra binds to the receptor, 
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it does not induce any cellular response, thus it antagonizes the effects of IL-1β (Dinarello 2013). 
IL-1ra is a 17-23 kDa protein secreted by numerous types of cells, including: immune cells such 
as macrophages, neutrophils, and mast cells (Roux-Lombard et al. 1989, McColl et al. 1992, 
Hagaman et al. 2001), epithelial cells (Perrier et al. 2002), keratinocytes (Gruaz-Chatellard et al. 
1991), hepatocytes (Molnar et al. 2004), fibroblasts (Palmer et al. 2004), and adipocytes (Juge-
Aubry et al. 2004). In order for IL-1ra to have its antagonist effect against IL-1β, it must be 
present in at least a 100-fold amount compared to IL-1β in vitro (Arend et al. 1990). Because IL-
1ra does not cause signal transduction, changing the levels of production is the means by which 
the function of IL-1ra can be regulated. This is controlled by regulatory molecules (Perrier et al. 
2006). 
 In periodontal disease, IL-1ra plays an anti-inflammatory role by antagonizing the effects 
of IL-1β. However, an increase in secretion of IL-1ra does not seem sufficient to overcome the 
release of IL-1β in many cases. Gilowski et al. (2014) found when comparing levels of IL-1β and 
IL-1ra in control and periodontitis groups that the periodontitis group showed nearly 300-times 
more moles/sample of IL-1ra when compared to IL-1β, suggesting that an increased amount of 
IL-1ra was not enough to control the effects of IL-1β in periodontitis. In control patients, IL-1ra 
showed nearly 800-times more moles/sample when compared to IL-1β. Holmlund et al. (2004) 
also reported that IL-1ra levels were higher in diseased sites when compared to non-diseased 
sites. On the other hand, Ishihara et al. (1997) showed no correlation between IL-1ra levels and 
alveolar bone loss in diseased sites. 
 Clinically, levels of IL-1ra do not seem to respond in a significant way to periodontal 
therapy. Toker et al. (2008) found that following SRP, IL-1ra levels did not significantly change in 
diseased sites. Yoshinari et al. (2004) also found no significant change in IL-1ra levels following 
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SRP. In regards to surgical therapy, Holmland et al. (2004) showed a non-significant decrease in 
IL-1ra levels following treatment of osseous defects caused by periodontal disease.  
 Patients experiencing periodontal disease may not have the proper levels of IL-1β and 
IL-1ra present in the periodontal tissues (Gilowski et al. 2014). The interaction of IL-1β and IL-1ra 
plays an important role in the body’s inflammatory responses. When the ratio between IL-1β 
and IL-1ra is imbalanced, a state of disease is encountered. Periodontal disease is not alone in 
showing an imbalance between the two cytokines. Others include kidney disease, liver disease, 
arthritis, graft-versus-host disease, inflammatory bowel disease, leukemia, cancer, central 
nervous system disease, arterial disease, and diabetes (Arend 2002). Better understanding of 
the ratio of IL-1β and IL-1ra and how to possibly alter it may be helpful in the treatment of 
periodontal disease.   
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CHAPTER 5: MATERIALS AND METHODS 
Patient Population and Study Design 
 Patients regularly attending the UNMC College of Dentistry for PMT were identified 
through review of their dental records by faculty (RR and AK). The inclusion criteria for the study 
included: subjects between the ages of 40-85 years, a periodontal diagnosis of moderate-severe 
chronic periodontitis, history of regular PMT at the College of Dentistry (≥2/year), at least one 
≥5 mm posterior interproximal pocket with a history of BOP, and no systemic diseases (e.g. 
rheumatoid arthritis, osteoporosis) or medications (e.g. chronic nonsteroidal anti-inflammatory 
drugs, steroids, bisphosphonates, calcitonin, methotrexate, antibiotics) with significant impact 
on periodontal inflammation or bone turnover.  Individuals meeting the inclusion criteria were 
invited to provide informed consent (UNMC IRB #314-12), stratified by gender and smoking 
status, and randomly assigned to test (SRP+MM) or control (SRP) groups by coin toss by a 
clinician not involved with clinical measurements (JH, Figure 1). She also identified the most 
posterior ≥5 mm interproximal site with a history of BOP as the experimental site. Standardized 
posterior vertical bitewing radiographs were exposed at the baseline and 24-month visits. 
Clinical measurements and GCF samples were obtained at each appointment by one of two 
calibrated clinicians (RR and AK). Saliva was sampled before treatment at the 24-month visit. Full 
mouth debridement and SRP of inflamed pockets were accomplished by the dental student 
assigned to the case. After completion of PMT, the test site (SRP+MM) received SRP and 
administration of MM in the experimental site by JH and the control site received SRP alone by 
JH. Periodontal maintenance therapy and SRP+MM or SRP at experimental site were performed 
at baseline, 6-month, 12-month, 18-month, and 24-month appointments. The study was 









Data Collection and Treatment Protocol 
During the baseline visit, the assignment of the test site was done by JH. Following the 
assignment, clinical data were collected by one of two trained and calibrated dentists (RR or AK). 
During data collection, supragingival plaque was removed from the test teeth with a dental 
explorer, then an absorbent paper slip (Periopaper, ProFLow, Amityville, NY) was inserted into 
the sulcus of the experimental site for 30 seconds to collect the GCF sample. Strips 
contaminated with blood were discarded. The paper strip was then placed into a sterile vial and 
frozen at -80⁰ C before further testing. Following GCF collection, gingival recession was 
measured at the test site using a UNC 15 probe (Hu-Friedy, Chicago, IL). Probing pocket depths 
were then measured at the same site. BOP was recorded as positive for sites that bled within 30 
seconds. Full-mouth measurements and PMT were then completed by the dental student 
assigned to the case. At the end of the PMT appointment, JH performed SRP at test sites and 
placed MM into the experimental site pockets of patients assigned to the experimental group.  
Participants then returned to the College for 6-month, 12-month, 18-month, and 24-month 
appointments. At each appointment, full mouth debridement and root planing of bleeding sites 
≥5 mm were provided, and at the baseline and 24-month visits radiographs were exposed. 
When exposing radiographs, a modified ring (XCP Rinn System) was used which allowed the 
rectangular radiographic cone to lock into a standardized film to source geometry. 
Measurements were made using digital imaging software (MiPACS Dental Enterprise Solution, 
Medicor Imaging). The measurement was made from the CEJ of the test site to the base of the 
bony defect (interproximal bone loss: IBL). Measurements were repeated in 10% of samples to 
ensure reproducibility. Saliva collection was done using a variation of the technique described 
by Navazesh (1993). At the beginning of the 24-month PMT, patients consented, rinsed with 
water and expectorated into a sterile collecting tube for five minutes while in a seated position. 
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Saliva samples were then centrifuged at 2,000 RPM for 5 minutes and the supernatant was 
pipetted into sterile vials. Vials were then frozen at -80⁰ C before further testing. At the 




Analysis of GCF and Salivary Samples 
 GCF samples from test sites were analyzed for both IL-1β and IL-1ra using standard 
ELISA techniques. ELISA kits utilized the quantitative sandwich technique (R&D Systems, Human 
IL-1β/IL-1F2 Quantikine® ELISA, R&D Systems, Minneapolis, MN; Human IL-1ra/IL-1F3 
Quantikine® ELISA, R&D Systems, Minneapolis, MN). All assay procedures were completed by 
individuals (JJ, MS, and LE) without knowledge of treatment group allocation. The ELISA tests 
were performed according the manufacturer’s instructions and protocol. GCF samples were 
allowed to thaw at room temperature. Sample strips were placed in 1 ml of phosphate buffer 
saline and gently agitated for 1 hour during the thawing process. 
IL-1β: 
 Two hundred µl of the standard or GCF sample were pipetted into each well. Wells were 
pre-coated with monoclonal antibody specific for IL-1β. Samples and standards then were 
covered with a plate sealer and allowed to incubate for 2 hours at room temperature. All wells 
were then aspirated and washed a total of 3 times. Following the wash, 200 µl of polyclonal 
antibody specific for human IL-1β conjugated to horseradish peroxidase with preservatives were 
added to each well for binding to a second epitope. The samples were again covered and 
incubated for 2 hours at room temperature. Aspiration and washing were again done 3 times. 
Two hundred µl of chromogen solution stabilized with hydrogen peroxide were added to each 
well. The samples then were incubated for 20 minutes protected from light. Fifty µl of stop 
solution were added to each well and gently agitated until uniform color was obtained. The 
plate was then read at a 450 nm wavelength and corrected for optical imperfections using 570 
nm wavelength readings subtracted from the 450 readings. All readings were done 30 minutes 
after the addition of the stop solution. 
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 Standard calibration curves were generated using computer software. The minimum 
detectable concentration for the ELISA was 1 pg/ml and the maximum detectable concentration 
was 262 pg/ml. All samples were analyzed separately and in duplicate. The standard curve was 
used to estimate the concentration of each sample. If a sample tested at a level lower than the 
minimum detectable concentration it was reported as 1 pg/ml (n=18). Cytokine levels higher 
than the maximum detectable level were tested with a 1:10 dilution. The average of each 
sample’s duplicate was used to determine the total IL-1β, and total IL-1β was calculated after 
adjusting for dilutions. 
IL-1ra: 
 IL-1ra is typically found in large quantities in GCF and saliva. Therefore, dilutions were 
used to prior to testing samples on the ELISA. GCF samples were diluted at 1:10 and 1:100, while 
salivary samples were diluted at 1:100 and 1:1000. One-hundred µl of each sample or standard 
were pipetted into wells pre-coated with monoclonal antibody specific for IL-1ra. The plate was 
then incubated for 2 hours at room temperature. Following incubation, the wells were aspirated 
and washed 4 times. Two-hundred µl of polyclonal antibody against IL-1ra conjugated to 
horseradish peroxidase with preservatives were added to each well for binding to a second 
epitope. The plate was again allowed to incubate for 2 hours at room temperature. Aspiration 
and washing were again performed 4 times. Two-hundred µl of chromogen solution stabilized 
with hydrogen peroxide were added to each well and allowed to incubate for 30 minutes at 
room temperature while protected from light. Fifty µl of stop solution were then added to each 
well. Samples and standards were gently agitated until a uniform yellow color was achieved. The 
plate then was read at a 450 nm wavelength and optical imperfections were corrected for by 
subtracting the 570 nm readings to obtain the optical density of each well. 
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Standard calibration curves were generated using computer software. The minimum 
detectable concentration for the ELISA was less than 1 pg/ml and the maximum detectable 
concentration was 2100 pg/ml. All samples were analyzed separately and in duplicate. The 
standard curve was used to estimate the concentration of each sample. No samples tested at a 
level lower than the minimum detectable concentration. Cytokine levels higher than the 
maximum detectable level were measured at the 1:1000 dilution. The average of each sample’s 
duplicate was used to determine the total IL-1ra. The levels measured in the 1:10 dilution in GCF 
and the 1:100 dilution in saliva were used unless the reading was over the maximum detectable 
level. 
IL-1β/IL-1ra ratio: 
 IL-1β levels were multiplied by a factor of 1000 to produce ng/ml and then divided by IL-
1ra levels. This created an IL-1β/IL-1ra ratio as a whole number which could be compared 
between subjects. This ratio has been used in the medical literature (Shingu et al. 1995, Lekovich 





 A power analysis was performed to optimize the power of detecting bone loss at 24 
months. Based on the data, it was assumed that the standard deviation of the change in average 
bone loss at 24 months was 0.57 mm. The significance level was set at 0.05/2=0.025 based on 
Bonferroni method to adjust for two tests conducted under the two treatments separately. The 
current study (with either 23 or 25 subjects per group) provided 82.4% power to detect a 
difference of 0.4 mm in average bone loss at 24 months after treatment in each group at a two-
sided significance level of 0.025 via one-sample t test. 
 The continuous data (bone loss, PD, CAL, GCF total IL-1β, GCF IL-1β/IL-1ra ratio) from 
baseline to 24 months were compared between groups using two-sample t-test or Wilcoxon 
rank sum test when the data was normally distributed. Categorical data (BOP and % plaque) 
were compared between groups using a chi-square test. 
 The Wilcoxon rank sum test was used to compare the change in radiographic bone loss 
and other clinical measurements from baseline to 24 months between the SRP+MM and SRP 
groups. The Fisher exact test was used to compare the relative frequency of having clinically-
significant bone loss (≥1 mm) between treatment groups. 
 Additionally, the linear mixed effects model, including visit time, treatment, and their 
interaction as covariates and AR(1) correlation structure was fit to evaluate the effects of 
treatment on changes in the continuous outcome over time. The total IL-1β values were log-
transformed to make the data normally distributed. The linear effects model was considered to 
account for the correlation between repeated measurements from the same patients. The 
generalized linear mixed effects model was used to estimate the difference in treatment effects 
on the change in categorical outcome over time. Stratified analysis by treatment group was used 
to evaluate the change of clinical outcome over time for each treatment group. 
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 Saliva total IL-1β and saliva IL-1β/IL-1ra ratios were only available at 24 month 
appointments. These values were log transformed and compared using two-sample t test 
between groups. 
 Spearman correlation was calculated between the GCF total IL-1β value and saliva total 
IL-1β at baseline and 24 months. Spearman correlation also was calculated between each of the 
total IL-1β measurements at baseline or 24 months and the changes in the clinical outcome 




CHAPTER 6: RESULTS 
Patient Characteristics 
 Following screening of the dental school records, 60 eligible patients were invited to 
participate and consented to participate in the study. Of the 60 participants randomized in the 
study, intervention was initiated on 55 subjects due to PD < 5 mm at baseline (Figure 1) and 48 
completed the 24-month PMT (13% dropout rate). 
 All patients were asked to report any symptoms or problems experienced during the 
study. No complications were reported or noted throughout the study. 
 Baseline characteristics of patients initiating intervention are displayed in Table 1. There 
were no significant differences between groups. 







Age (years) 67.33 (10.52) 66.75 (12.07) 
Male/Female 22 (81.5%) 16 (57.1%) 
   Current Smokers 8 (29.6%) 4 (14.3%) 
 
Inflammatory Biomarker Outcomes 
 The mean baseline and 24-month measurements of inflammatory biomarkers are 










Figure 2: Levels of IL-1β at baseline and 24 months (mean ± standard deviation). GCF=gingival 
crevicular fluid, SRP=scaling and root planing, M=minocycline. 
 







 Baseline and 24-month results for PD, CAL, BOP, and IBL are reported in Figures 4-6. 
Both SRP+MM and SRP alone significantly reduced PD, CAL, and BOP from baseline to 24 
months, but there were no differences between groups at experimental sites. Both groups had 
stable interproximal bone heights over 24 months of 6-month PMT at experimental sites. Only 
one site in each group lost 0.5 mm and no sites lost ≥ 1 mm. 
Figure 4: Clinical measurements at baseline and 24 months (mean ± standard deviation). 




Figure 5: Percent bleeding on probing at baseline and 24 months. SRP=scaling and root planing, 
M=minocycline. 
 
Figure 6: Interproximal bone loss at baseline and 24 months (mean ± standard deviation). 





A significant Spearman correlation was found between GCF total IL-1β at baseline and 
change in bone loss at 24 months (r=0.34, p=0.017). A concurrent correlation was found 
between salivary total IL-1β at 24-months and change in PD at 24 months (r=0.34, p=0.031), and 
a trend toward a change in CAL (r=0.31, p=0.055). 
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CHAPTER 7: DISCUSSION 
 The aim of this study was to determine the effect of MM when used in conjunction with 
SRP in patients receiving regular PMT compared to SRP alone during PMT. Patients included in 
the study were patients who regularly attended PMT appointments at the University of 
Nebraska Medical Center College of Dentistry. All patients had received periodontal treatment 
prior to enrolling in the study. Each patient had at least one posterior pocket ≥5 mm with a 
history of BOP. Patients received PMT at 6 month intervals. 
 The primary outcome measure in this study was change in interproximal bone height. 
Neither group demonstrated a significant change from baseline to 24 months even though the 
study was powered to detect changes of 0.4 mm mean bone loss. In fact, only one site in each 
group lost between 0.5 and 1.0 mm IBL during the 24 months. Also, there was no difference 
between groups at baseline and 24 month appointments in IBL. Mean changes of <0.2 mm in 
the current study are far short of a 1 mm change in bone height needed to achieve 
reproducibility in bone height changes when investigating a series of radiographs (Hausmann et 
al. 1997). Previous studies have indicated that bone height changes during regular PMT average 
<1 mm over a 14 year period (Lindhe & Nyman 1984) and patients not receiving regular PMT 
experienced a significant amount of alveolar bone loss (Becker et al. 1984a). Payne et al (2013) 
reported that in post-menopausal women receiving sub-antimicrobial doses of doxycycline or 
placebo and regular PMT, alveolar bone height remained stable in both groups. The test group 
and the control experienced no significant loss or gain in alveolar bone height during the 2-year 
study. At 1 year, 94% of sites showed no change in alveolar bone height and at 2 years 90% of 
sites showed no change in alveolar bone height. In the current study, 96% of subjects showed no 
change in alveolar bone height during the 24 months. Results in the present study indicate a 
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population with stable alveolar bone height at experimental sites, presumably supported by 
repeated SRP. 
 When evaluating the baseline and 24 month clinical and inflammatory biomarker 
measurements, no significant differences were found between the two groups. However, both 
groups experienced a statistically significant decrease in PD, CAL, and BOP. No changes were 
found from baseline to 24 months in IL-1β levels in either group. Meinberg et al. (2002) reported 
an improvement in PD of 0.9 ± 0.1 mm in the SRP+MM group at one year with a 0.4 ± 0.1 mm in 
the SRP group. CAL levels were not reported. However, Meinberg et al. only followed patients 
for 1 year. Meinberg et al. also administered 4 doses of MM over a 6 month period with only 
one session of SRP in contrast to the current study which administered the 4 doses of MM and 
the 4 sessions of SRP every 6 months for 2 years. The current study layout may better 
approximate a clinically feasible situation. In this study, it was shown that at 24 months a PD 
reduction of 1.1 ± 0.9 mm in the SRP+MM group and 1.5 ± 0.6 mm in the SRP group was 
achieved. This reduction appears to coincide with Meinberg et al. SRP+MM data at one year, but 
6-month SRP promoted more 2-year PD reduction than the one episode of SRP caused at one 
year. In fact, PD numerically reduced further (not statistically significant) at the 24-month PMT 
following the initial improvements at 6 months when evaluating data from the current study 
previously published (Killeen et al. 2016).  Previous reports (Lindhe et al. 1982, Cobb 1996) also 
showed that at 1 year post initial therapy a 1 mm decrease in PD can be expected following 
acceptable SRP without adjunctive therapy. The reductions in PD in both SRP+MM and SRP 
groups were significant, however, there was no difference between the two groups at 24 




 When considering CAL, the current study showed a significant gain in CAL in both 
groups. The SRP+MM group showed a gain of 1.0 ± 1.0 mm and the SRP group showed a gain of 
1.6 ± 0.8 mm at the end of 24 months. Both groups showed a significant improvement in CAL 
gain, but again, the difference between groups was not statistically significant. This 
improvement in CAL falls in line with previous data regarding post-SRP response to therapy 
(Cobb, 1996). Previous studies evaluating PMT patients showed results ranging from no change 
in CAL during a 14-year therapy period (Lindhe & Nyman 1984) to a slight gain (0.3-0.4 mm) in 
CAL over a 30-year PMT period (Axelsson et al. 2004). 
 The current study showed that both the SRP+MM and SRP groups demonstrated a 
significant decrease in the percentage of BOP. The SRP+MM group showed a decrease of 55% 
and the SRP group showed a decrease of 48%. There was no statistically significant differences 
in BOP between the groups at baseline or 24 months. This reduction in BOP following therapy is 
consistent with previous findings (Cobb 1996). The presence of BOP is not a reliable predictor of 
disease activity, but the reduction and elimination of BOP may be used as a criterion for stability 
(Chavez et al. 1990, Lang et al. 1990). Using BOP as a sign of periodontal stability, this study 
would reinforce the idea that repeated SRP can lead to a reduction in BOP and thus increase 
periodontal stability regardless of the addition of MM in PMT. This finding is in agreement with 
previous studies in regards to BOP and PMT. Miyamoto et al. (2006) showed that patients who 
were compliant with PMT showed a greater decrease in BOP levels when compared to poorly 
compliant patients. Novaes et al. (1996) found that patients who were compliant with PMT were 
able to maintain the amount of BOP between appointments whereas non-compliant patients 
saw an increase in the amount of BOP between appointments. 
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 Periodontal disease and severity of disease have been associated with GCF IL-1β levels 
(Ishihara et al. 1997, Yoshinaria et al. 2004, Toker et al. 2008). IL-1β is a pro-inflammatory 
cytokine released by various cells in the periodontium. IL-1ra is an anti-inflammatory cytokine 
that has an antagonistic effect on IL-1β. In the current study, total IL-1β/30 second sample was 
measured as well as the IL-1β/IL-1ra ratio. At baseline, there was no significant difference 
between total IL-1β in the SRP+MM group (9.9 ± 2.1 pg, log transformed) and SRP group (10.0 ± 
2.0 pg, log transformed). At 24 months, no significant difference was noted between the 
SRP+MM group (10.3 ± 2.2 pg, log transformed) and the SRP group (10.5 ± 2.2 pg, log 
transformed). When looking at the IL-1β/IL-1ra ratio, there was no significant difference 
between groups at baseline (SRP+MM 0.89 ± 1.2 log scale, SRP 0.51 ± 1.7 log scale) or 24 
months (SRP+MM 1.2 ± 2.4, SRP 1.0 ± 2.0). Neither group experienced a significant change from 
baseline to 24 months in the IL-1β/IL-1ra ratio. Many studies report that SRP produces a 
reduction in GCF IL-1β at various time periods (Engebretson et al. 2002, Toker et al. 2008). These 
studies followed patients for 6 weeks and 24 weeks, respectively. In addition, these studies were 
following patients after initial SRP rather than starting with patients in ongoing PMT. These 
findings suggest that baseline IL-1β levels were already lowered by previous PMT and that BOP 
may be a simpler and more sensitive measure of local inflammation.  
Salivary levels of IL-1β have been shown to reflect periodontal disease severity (Kinney 
et al. 2011, Sexton et al. 2011, Rathnayake et al. 2013). In the current study, total IL-1β was 
measured at the 24-month PMT appointment. Results were similar between the SRP+MM group 
(13.2 ± 1.2 pg, log transformed) and SRP group (12.8 ± 1.2 pg, log transformed). Much like GCF 
IL-1β, evidence shows that periodontal therapy may reduce the amount of IL-1β in saliva (Sexton 
et al. 2011). These findings again suggest that salivary IL-1β at 24 months may have already 
been lowered by previous PMT. 
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 During the current study several attempts were made to avoid any bias. The 
manufacturer of MM did not support the study in anyway. Clinical and inflammatory biomarker 
data were measured and collected by different clinicians masked to experimental groups (RR 
and AK) than the clinician providing randomization and therapy (JH). ELISA testing was carried 
out by individuals not involved with collection or providing of therapy (JJ, MS, or LE). One 
potential area of bias may arise in the fact that the clinician providing therapy (JH) did both the 
SRP and the application of MM to the test sites. Due to the knowledge of what sites received 
MM and those that did not, the clinician may have provided different levels of SRP intensity in 
each group. This does not appear to be the case due to the fact that both test and control sites 
experienced a similar improvement in CAL and PD. 
 Current smokers were included in both the SRP+MM group (n=8) and SRP group (n=4). 
Smoking has been shown to affect the severity of periodontal disease and the patient’s 
response to therapy. Cigarette smoking has been shown to be associated with a 2- to 8-fold 
increased risk for CAL loss and BL (Johnson & Guthmiller 2007). Bergstrom (2004) found that 
over a 10-year period smokers lost more periodontal bone height (0.74 ± 0.59 mm) than non-
smokers (0.27 ± 0.29 mm). Labriola et al. (2005) found that PD ≥ 5 mm were reduced more in 
non-smokers when compared to smokers during SRP by an average of 0.433 mm. Previous data 
published from this study found no difference between the clinical outcomes of smokers and 
non-smokers at 1 year (Killeen et al. 2016).  
 This study does present with several limitations. Patients selected for this study were 
receiving regular PMT at the College of Dentistry. This regular care suggests that patients were 
likely stable periodontally. In order to avoid this limitation, future studies may consider enrolling 
patients that present for initial SRP and following them through a period of PMT. Several 
34 
 
patients also dropped out of the study for various reasons. These drop outs may have affected 
the power of the study. However, the statistical analysis showed that the study had sufficient 
power with the amount of patients that were retained through the whole study. Based on our 
data, it was assumed the standard deviation of the change in average bone loss at 24 months 
was 0.6 mm. The significance level was set to be 0.05/2=0.025 based on Bonferroni method to 
adjust for two tests conducted under the two treatments separately. Our study provided 82.4% 
power to detect a difference of 0.4 mm in average bone loss at 24 months after treatment in 
each group at a two-sided significance level of 0.025 via one-sample t test. 
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CHAPTER 8: CONCLUSIONS 
 Scaling and root planing of inflamed moderate periodontal pockets, with or without the 
addition of MM at 6 month intervals, produced a long-term improvement in BOP, PD, CAL, and 
stable interproximal bone heights after 24 months of 6-month PMT. SRP with or without MM 
did not demonstrate a significant improvement in total IL-1β or IL-1β/IL-1ra ratios for patients 
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Appendix A: Raw Clinical Data 







N1 1 77 1 2 34366 16398 433 
N2 2 75 1 2 124981 19241.5 156716 
N3 2 71 2 2 126209.5 132026.5 225227 
N4 2 66 2 1 61705.5 1000 8319 
N5 1 67 1 2 57310 78122.5 115997 
N6 1 48 1 2 21503.5 1000 45353 
N7 2 59 2 3 80772 1000 24477 
N8 1 75 1 2 80708 27644 79996.5 
N9 1 57 1 3 172163 175524.5 251209 
N10 2 52 2 2 48585 75924.5 55242 
N11 1 54 2 1 91566 39601   
N12 2 40 1 1 1000   1000 
N14 2 72 1 2 24154 17367.5 61123.5 
N15 2 61 1 1 1000 2178.5 433.5 
N17 2 69 1 3 330525 34176.5 196984.5 
N19 2 75 2 3 42653 1000 1000 
N20 1 60 1 1 1897300 215330 73289.5 
N21 2 82 2 3 138618 1000 24489 
N22 1 60 1 1 1000 1000 87215 
N23 1 74 1 1 1000 1000 1000 
N24 2 57 1 2 1000 60756 38778 
N25 1 69 1 1 2692.5 47436 84672 
N26 2 73 2 2 9897.5 4448.5 64328.5 
N27 2 45 1 2 39444 26305.5 50039.5 
N28 1 51 2 1 1000 1000 1000 
N29 1 69 1 2 1000 1000 1000 
N30 2 84 1 2 4206 78254 34176.5 
N31 1 69 2 2 12766 25916 7677.5 
N33 1 79 1 2 1000 1268 7347 
N34 2 71 1 2 13162.5 7677.5 1000 
N35 2 62 2 1 1000 13625 1000 
N36 1 67 1 3 168452 31202.5 21752.5 
N37 2 74 1 2 262000 110697.5 79970 
N38 1 60 1 3 1000 1000 1000 
N39 2 76 2 2 1000 1000 1000 
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N40 1 73 1 2 25718 70652.5 187086.5 
N41 1 59 2 3 21752.5 58494 16730.5 
N42 2 50 1 2 89551.5 222968 1000 
N43 1 69 2 2 67018.5 1000 60410 
N44 2 81 1 2 62185 7782 3217 
N45 2 46 2 3 45051 17474 147791 
N46 1 56 1 1 15098 1984 20163 
N47 1 83 1 2 153932 88011 76817 
N48 2 70 1 2 1000 38860 11722 
N49 2 65 2 3 3530 17162 7594 
N50 1 85 1 3 98578 157496 38548 
N51 1 77 1 2 67562 36234 23790 
N52 2 75 1 2 262500 119464 62873 
N53 2 83 1 3 53993 152369 61309 
N54 1 66 1 1 34233 1108 3922 















40485.5 140898 74205 18160.1 15158.765 
3105 86781.5 672870 30204.55 16679.94 
87407.5 262500 403110 22945.6 32301.55 
1000     18375.15 1676.335 
15148 163107.5   8374 22300.4 
6232.5 16868.5 1119345 18697.8 1003.815 
1000 301 72040 20687.25 1660.32 
168112 179217 473795 31925.2 12933.04 
262500 262500 98725 36925.8 42087.7 
63477 20153   14557.55 16762.1 
13271.5 127603 1215275 13858.5 21977.75 
32821.5 262500   447.85   
95877 254200 532220 11438.9 22246.6 
1000 2674.5 14335 1276.025 11008.7 
259130 178260.5 129020 35689.1 20902.4 
66471 1301 341080 4407.525 4230.115 
227921 233865.5 876270 92953.95 24988.9 
96629.5 150132 974365 65854 3148.755 
1079.5 2964.5 95120 56.74 833.97 
11228.5 58279 228555 251.05 5894.39 
17246 60309 33815 504.495 3106.51 
63934 1000 159315 1602.75 26279.35 
40952.5 48129.5 276165 9163.815 9476.395 
47694 61179 260290 1340.86 11157.57 
1000 17536   580.53 893.105 
1000 1000 97280 605.87 225.705 
7893.5 1000 1214555 1340.86 10667.575 
66834 130558 579100 2992.095 32247.8 
37256.5 150349.5 484615 2301.57 12050.52 
34282.5 1000 268225 18767.435 16350.605 
10648.5 53421.5 551695 2558.95 16256.44 
22756 85755 1803120 5451.61 2841.59 
5501.5 199516.5 810635 130792.4 55793.4 
2809 1000   1083.74 10506.26 
39514.5 7202.5 1181290 8779.945 2916.765 
144529 262500 791160 65433.4 10443.485 
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150481     25451.6 43237.3 
136451 262500 1572310 14787.51 24294.8 
214255 142545 3163000 19985.27 3444.075 
56237.5 116468.5 1200130 1162.58 2518.99 
109807.5 112500 289145 51592.3 14154.93 
158134     3230.45 1541.57 
119586.5 1000 1047935 192321.1 198063 
75653     6096.21 2751.705 
  145379 1324185 167578.7 58900.2 
256063 240048 3763750 124879.9 161941.2 
27185 9895 1583130 163402.8 184386 
262500 262500 439175 210000 210000 
1000     210000 179271.3 
221199.5 1000 584870 10923.47 89175.7 















11523.95 7863.335 3186.265 434803 1.89239046 
44023.4 1599.635 6595.295 2058341 4.137820295 
81124.6 51382.9 2811.55 624669.5 5.500379158 
18313.205 885.8     3.358095036 
33699.6 522.76 5798.8   6.843802245 
12352.95 3046.085 1191.82 1703990.5 1.150055087 
13253.29 1535.915 280.625 292019.5 3.90443389 
26601.95 1382.985 1841.77 2100000 2.52803428 
45260.1 465.41 465.41 1237769 4.662404064 
31172.4 2236.835 18829.585   3.337443457 
  2134.88 3817.095 2100000 6.607208572 
8625.71 363.46 643.825   2.232890477 
43001.8 32710.4 32656.4 1573489.5 2.111566672 
21977.75 20985.65 22390.4 456809 0.783683705 
4737 37465.2 24065.4 583216.5 9.26123102 
5936.635 17041.3 8890.01 2100000 9.677313231 
1332.41 35303.95 28550 1546878 20.4111821 
2346.185 24011.4 76205.7 2100000 2.104929086 
14283.37 5042.95 9496.115 1394882 17.62425097 
487.6 10750.405 25416.2 1537154 3.983270265 
4086.495 13865.095 19345.265 427638.5 1.9821802 
665.005 17797.75 13301.085 1039714.5 1.679925129 
7406.605 18789.675 13475.25 937360.5 1.080063271 
20653.25 23957.3 31900 2075741 29.41694137 
10 631.88 16987.3   1.722563864 
22.951 5556.455 16014.75 2100000 1.650519088 
4018.91 7602.045 8687.98 2100000 3.136792805 
3343.635 20445.3 14496.45 2100000 4.26657576 
16733.53 18716.3 28928.2 1754656 0.434486025 
7988.98 5783.74 3283.575 698876 0.70134784 
3714.005 11196.565 22984.75 1457829.5 0.390785283 
19037.37 13570.465 33088.65 2100000 30.89949575 
47599.4 19028.185 30456.75 1845751 2.003174496 
5182.94 6838.19 5793.56   0.922730544 
1466.66 17766.595 20769.435 2100000 0.11389593 
39622.3 20865.865 43571.7 2100000 0.393040863 
50 
 
23282.6 42114.5     0.854661397 
12100.74 16143.41 46902.45 2100000 6.055887705 
22125.8 37326.45 27334.15 2100000 3.353394775 
2425.9 13459.52 30248.55 2100000 53.48879217 
13915.57 17830.88 15572.875 2100000 0.8732117 
18623.14 12093.47     4.673652278 
79779.9 34620.2 7264.075 1645649.5 0.800390597 
120912.8 8951.55     0.164036344 
57229.8   35557 2100000 0.02106473 
71428 19839.85 30456.75 2100000 0.789382439 
19175.01 17927.305 5865.885 2100000 0.413469047 
72158.8 37534.65 48151.55 1798156.5 1.25 
17020.7 2209.69     0.257109524 
151083.8 45028.95 1735.59 2100000 3.133894266 












Ratio Saliva Ratio 
1.081750393 0.037573922 5.148642402 44.22042737 0.170663496 
1.153571296 3.559834088 1.941067806 13.15809225 0.326899187 
4.0873116 2.776309529 1.70110095 93.36486991 0.645317244 
0.596539475 0.454262375 1.128923007   
3.503188284 3.442088333 28.9769684 28.1278023  
0.996199499 3.671430711 2.04606897 14.15356346 0.656896268 
0.602293534 1.846862175 0.651077696 1.072605791 0.246695854 
2.137471159 3.007166768 121.557356 97.30693843 0.225616667 
4.170446472 5.55034125 564.0188221 564.0188221 0.07976044 
4.529533889 1.772144589 28.37804308 1.070283811  
1.801867798  6.216508656 33.42934876 0.578702381 
 0.115932486 90.30292192 407.719489  
0.780681093 1.421417243 2.931086138 7.784079078 0.33824185 
0.197888942 0.019724494 0.04765161 0.119448514 0.03138073 
1.635051477 41.58423053 6.916551893 7.407335843 0.22122145 
0.236400192 0.168445592 3.900582702 0.146344042 0.162419048 
8.61702596 55.00521611 6.455963143 8.191436077 0.566476477 
0.317585839 10.43779583 4.024317616 1.970088852 0.463983333 
1.1990839 6.106052003 0.214061214 0.312180297 0.068192148 
0.169652839 2.050861362 1.044472278 2.292986363 0.148687119 
19.55763864 9.489305627 1.243842902 3.117507049 0.079073797 
1.805067477 127.3253585 3.59225183 0.075181837 0.153229564 
0.469429567 8.685288334 2.179521466 3.571696258 0.294619839 
2.357637012 2.42283902 1.990791951 1.917836991 0.125396184 
1.119689174 100 1.582578971 1.032300601  
4.430562017 43.57108623 0.179970863 0.062442436 0.04632381 
7.33568782 8.503922705 1.038339026 0.115101554 0.578359524 
0.803651722 2.296153737 3.268917551 9.006204967 0.275761905 
0.105223675 0.439058585 1.990591089 5.197333398 0.276188039 
0.46955449 0.125172425 5.927393002 0.304546112 0.383794836 
0.838129381 0.269251118 0.951050612 2.324214969 0.378435887 
10.98064816 1.142621066 1.676876953 2.591674184 0.858628571 
1.984060839 1.680063194 0.289123739 6.550813859 0.439189793 
0.095181349 0.192940686 0.410781215 0.172605445  
0.342845584 0.681821281 2.224089647 0.346783627 0.562519048 
6.765222529 4.721747602 6.926576013 6.024552634 0.376742857 
52 
 
1.352859684 0.718583835 3.573139892   
9.177601791 0.082639574 8.452427337 5.596722559 0.748719048 
0.290353723 2.730296758 5.740031533 5.214905164 1.506190476 
3.089333423 1.326105775 4.178269359 3.850382911 0.571490476 
1.234481555 10.6205495 6.158277101 7.224099596 0.137688095 
1.286999617 1.082685304 13.07598233   
0.444358613 0.962861573 3.454240588 0.137663777 0.636791127 
14.12215336 0.096945898 8.451385514   
0.291374223 0.132693107  4.088618275 0.630564286 
0.972550531 0.539676317 12.90649879 7.8816026 1.792261905 
0.196511666 1.240677319 1.516401935 1.686872484 0.753871429 
0.56887619 0.871314379 6.993537971 5.451537905 0.24423625 
0.849935266 3.602025769 0.452552168   
0.012424909 0.025959103 4.912384144 0.576172944 0.278509524 



























5 3 5 4 1 0 1 
5 5 5 5 0 0 0 
3 6 6 4.5 0 0 0 
3 4 4 3.5 1 1 1 
3 6 6 4.5 0 0 0 
3 4 4 3.5 0 0 0 
4 6 6 5 0 2 2 
3 6 6 4.5 2 0 0 
5 5 5 5 0 0 0 
2 5 5 3.5 3 0 0 
5 6 6 5.5 0 0 0 
6 5 6 5.5 1 0 1 
5 7 5 6 1 0 1 
7 4 7 5.5 1 0 1 
5 5 5 5 0 1 0 
5 4 5 4.5 1 0 1 
5 6 6 5.5 1 0 0 
5 4 5 4.5 0 0 0 
3 5 5 4 1 1 1 
5 4 5 4.5 0 0 0 
4 6 6 5 1 0 0 
5 5 5 5 0 0 0 
5 4 5 4.5 1 2 1 
4 6 6 5 0 0 0 
5 3 5 4 0 0 0 
5 4 5 4.5 0 0 0 
5 5 5 5 0 0 0 
5 5 5 5 0 0 0 
3 5 5 4 2 0 0 
4 6 6 5 0 0 0 
3 5 5 4 1 0 0 
5 5 5 5 0 0 0 
5 6 6 5.5 0 0 0 
3 5 5 4 0 0 0 
3 5 5 4 1 1 1 
5 4 5 4.5 0 3 0 
54 
 
5 5 5 5 0 0 0 
5 5 5 5 0 0 0 
4 6 6 5 0 0 0 
3 5 5 4 0 0 0 
6 4 6 5 0 0 0 
5 7 7 6 1 0 0 
6 7 6 6.5 0 0 0 
4 5 5 4.5 0 0 0 
5 3 5 4 0 0 0 
5 3 5 4 0 0 0 
3 5 5 4 2 0 0 
7 6 7 6.5 0 1 0 
5 5 5 5 0 0 0 
3 5 5 4 2 1 1 



























0.5 4.5 1 0 1 0.5   
0 5 0 1 1 0.5   
0 4.5 1 1 1 1   
1 4.5 0 0 0 0   
0 4.5 0 1 1 0.5 4 
0 3.5 0 0 0 0 3 
1 6 1 1 1 1 5 
1 5.5 0 1 1 0.5 4 
0 5 1 1 1 1 3 
1.5 5 0 1 1 0.5 3 
0 5.5 0 1 1 0.5 8 
0.5 6 0 1 0 0.5 5 
0.5 6.5 1 1 1 1 4 
0.5 6 0 0 0 0 5 
0.5 5.5 1 1 1 1 3 
0.5 5 0 0 0 0 4 
0.5 6 1 0 0 0.5 5 
0 4.5 1 1 1 1 5 
1 5 0 1 1 0.5 3 
0 4.5 1 1 1 1 3 
0.5 5.5 1 1 1 1 4 
0 5 0 1 1 0.5 4 
1.5 6 0 0 0 0 4 
0 5 1 1 1 1 3 
0 4 0 0 0 0 2 
0 4.5 1 1 1 1 3 
0 5 1 1 1 1 6 
0 5 0 1 1 0.5 4 
1 5 1 1 1 1 3 
0 5 0 1 1 0.5 4 
0.5 4.5 1 1 1 1 3 
0 5 1 1 1 1 3 
0 5.5 1 1 1 1 3 
0 4 0 1 1 0.5 3 
1 5 0 0 0 0 3 
1.5 6 0 0 0 0 3 
56 
 
0 5 1 1 1 1 4 
0 5 1 1 1 1 3 
0 5 0 1 1 0.5 5 
0 4 1 1 1 1 3 
0 5 1 1 1 1 5 
0.5 6.5 1 1 1 1 3 
0 6.5 1 1 1 1 4 
0 4.5 1 1 1 1 4 
0 4 1 0 1 0.5 3 
0 4 1 1 1 1 4 
1 5 1 1 1 1 3 
0.5 7 1 1 1 1 5 
0 5 1 1 1 1 5 
1.5 5.5 0 1 1 0.5 2 




























          3 3 
          3 5 
          3 5 
          3 4 
6 2 0 1 1 4 6 
3 2 0 0 0 3 4 
3 0 0 0 1 4 5 
6 0 0 0 1 4 6 
3 1 0 1 1 6 6 
5 2 0 0 0 2 5 
7 0 0 1 1 6 6 
6 0 0 1 1     
6 1 0 1 1 5 6 
5 1 0 0 0 5 4 
4 0 0 0 1 4 5 
5 0 0 0 0 5 5 
5 0 0 0 0 4 5 
4 1 0 1 1 4 4 
3 0 0 0 0 4 4 
3 1 0 0 0 4 2 
4 2 0 0 0 3 5 
5 0 0 0 0 3 4 
4 1 1 0 0 3 4 
5 0 0 1 1 3 5 
2 0 0 0 0 3 3 
3 0 0 0 1 4 3 
6 0 0 1 1 4 5 
4 0 0 0 0 4 5 
4 1 0 1 1 3 4 
6 0 0 0 0 4 4 
3 0 0 0 0 3 3 
4 0 0 0 0 4 4 
3 1 1 0 0 4 5 
4 0 0 0 0 3 4 
4 1 1 0 0 3 5 
4 0 2 0 0 4 5 
58 
 
3 0 0 0 0 3 4 
4 0 0 0 1 4 6 
4 0 0 0 0 4 6 
5 1 0 1 0 4 6 
3 0 0 1 1 5 4 
7 0 2 0 0 5 6 
5 4 0 0 0 3 5 
4 0 0 1 0 3 4 
3 0 0 0 0 3 3 
5 0 0 1 1 4 4 
5 2 0 1 1 4 4 
3 0 0 1 1 7 4 
4 0 0 1 1 4 4 
4 0 0 0 0 3 4 

























3 3 1 1 1 1 
5 4 0 0 0 0 
5 4 0 0 0 0 
4 3.5 0 0 0 0 
6 5 1 0 0 0.5 
4 3.5 0 0 0 0 
5 4.5 1 0 0 0.5 
4 5 0 0 0 0 
6 6 0 0 0 0 
5 3.5 4 0 0 2 
6 6 0 0 0 0 
          
5 5.5 0 0 0 0 
5 4.5 0 0 0 0 
4 4.5 1 0 1 0.5 
5 5 1 1 1 1 
5 4.5 0 0 0 0 
4 4 1 0 1 0.5 
4 4 0 0 0 0 
4 3 0 0 0 0 
5 4 1 0 0 0.5 
4 3.5 0 0 0 0 
3 3.5 2 2 2 2 
5 4 0 0 0 0 
3 3 0 1 0 0.5 
4 3.5 1 0 1 0.5 
5 4.5 1 0 0 0.5 
5 4.5 0 0 0 0 
4 3.5 1 0 0 0.5 
4 4 0 1 1 0.5 
3 3 1 0 0 0.5 
4 4 0 0 0 0 
5 4.5 1 0 0 0.5 
4 3.5 0 0 0 0 
5 4 0 0 0 0 
4 4.5 0 0 0 0 
60 
 
4 3.5 0 0 0 0 
6 5 0 0 0 0 
6 5 0 0 0 0 
6 5 0 0 0 0 
5 4.5 0 0 0 0 
6 5.5 1 0 0 0.5 
3 4 1 2 1 1.5 
4 3.5 0 1 1 0.5 
3 3 0 0 0 0 
4 4 0 0 0 0 
4 4 2 0 0 1 
7 5.5 0 2 0 1 
4 4 0 0 0 0 
4 3.5 2 0 0 1 






















4 1 1 1 1 2 
4 1 0 0 0.5 4 
4 0 1 1 0.5 3 
3.5 0 0 0 0 3 
5.5 1 1 1 1 3 
3.5 0 0 0 0 3 
5 0 1 1 0.5 4 
5 0 0 0 0 5 
6 1 1 1 1 6 
5.5 0 1 1 0.5 2 
6 0 0 0 0 2 
          
5.5 1 0 1 0.5 5 
4.5 0 0 0 0 3 
5 0 1 0 0.5 3 
6 0 0 1 0 5 
4.5 0 0 0 0 3 
4.5 0 0 0 0 4 
4 0 0 0 0 4 
3 1 0 1 0.5 2 
4.5 0 0 0 0 4 
3.5 0 0 0 0 4 
5.5 0 0 0 0 2 
4 0 0 0 0 3 
3.5 0 0 0 0 3 
4 0 0 0 0 1 
5 1 1 1 1 6 
4.5 0 0 0 0 3 
4 0 0 0 0 3 
4.5 0 0 0 0 6 
3.5 0 0 0 0 3 
4 0 0 0 0 3 
5 1 0 0 0.5 3 
3.5 0 0 0 0 3 
4 0 0 0 0 3 
4.5 1 0 1 0.5 3 
62 
 
3.5 0 0 0 0 2 
5 1 1 1 1 3 
5 1 1 1 1 3 
5 1 0 0 0.5 3 
4.5 1 1 1 1 5 
6 0 1 1 0.5 3 
5.5 1 1 1 1 2 
4 0 0 0 0 3 
3 0 0 0 0 1 
4 1 1 1 1 4 
5 1 0 0 0.5 4 
6.5 1 1 1 1 4 
4 1 1 1 1 4 
4.5 0 0 0 0 3 























2 4 3 0 1 4 
5 0 0 0 0 4 
4 0 0 0 1 3 
4 0 0 0 0 3 
4 0 0 0 0 2 
4 0 0 0 0 3 
4 1 0 0 0 4 
5 1 0 0 1 5 
4 0 0 1 1 6 
5 3 0 0 1 2 
2 0 0 0 0   
          6 
6 1 0 0 0 5 
3 1 1 0 0 5 
5 0 0 0 0 5 
4 1 1 0 1 5 
5 0 0 0 0 4 
4 1 0 0 0 4 
4 0 1 1 0 4 
3 0 0 0 0 4 
3 1 0 0 0 3 
4 0 0 0 0 4 
3 2 2 0 0 2 
5 0 0 1 1 4 
3 0 0 0 0 3 
1 1 1 0 0 4 
6 0 0 1 1 4 
3 0 0 0 0 4 
3 1 0 1 1 3 
5 0 0 0 0 4 
3 1 0 0 0 3 
4 0 0 0 1 3 
5 0 0 1 0 4 
4 0 0 0 0 3 
4 1 0 0 0 3 
5 0 0 0 0 4 
64 
 
2 1 1 0 0 4 
3 0 0 0 1 4 
5 0 0 1 1 4 
4 1 0 1 0 2 
3 0 0 1 1 4 
5 0 1 0 1 6 
4 2 2 1 1 3 
3 0 1 0 0 3 
2 1 0 0 0 2 
4 0 0 1 1 4 
4 1 0 1 0 3 
3 0 0 0 1 5 
4 0 0 0 1 4 
4 0 0 0 1 3 


















Site, F rec 
12 
month, 




3 4 3.5 1 1 1 
5 5 4.5 0 1 1 
5 5 4 0 0 0 
3 3 3 0 1 1 
5 5 3.5 0 0 0 
4 4 3.5 0 0 0 
5 5 4.5 0 0 0 
6 6 5.5 2 0 0 
5 6 5.5 0 0 0 
5 5 3.5 5 0 0 
           
5 6 5.5 0 0 0 
5 5 5 0 0 0 
6 5 5.5 0 0 0 
4 5 4.5 0 0 0 
4 4 4.5 2 1 1 
5 4 4.5 0 0 0 
3 4 3.5 0 0 0 
5 5 4.5 0 1 1 
3 4 3.5 0 0 0 
4 4 3.5 1 0 0 
5 5 4.5 0 0 0 
2 2 2 2 2 2 
4 4 4 0 0 0 
3 3 3 0 1 0 
3 4 3.5 0 0 0 
4 4 4 1 1 1 
5 5 4.5 0 0 0 
3 3 3 2 2 2 
5 5 4.5 1 0 0 
4 4 3.5 1 0 0 
4 3 3.5 0 0 0 
4 4 4 0 1 0 
3 3 3 0 0 0 
3 3 3 2 1 1 
3 4 3.5 1 2 1 
66 
 
5 5 4.5 0 1 1 
4 4 4 0 0 0 
5 5 4.5 0 0 0 
3 3 2.5 0 0 0 
5 4 4.5 0 0 0 
5 5 5.5 1 1 1 
5 3 4 2 1 2 
4 4 3.5 0 0 0 
2 3 2 0 0 0 
4 4 4 0 1 0 
4 4 3.5 1 0 0 
6 5 5.5 1 2 1 
4 4 4 0 0 0 
4 4 3.5 2 1 1 
































1 4.5 0 0 0 0 3 
0.5 5 0 0 0 0 3 
0 4 1 1 1 1 3 
0.5 3.5 0 1 1 0.5 3 
0 3.5 1 1 1 1 3 
0 3.5 0 0 0 0 3 
0 4.5 1 1 1 1 3 
1 6.5 1 0 0 0.5 4 
0 5.5 0 1 0 0.5 3 
2.5 6 0 1 1 0.5 2 
           
0 5.5 1 1 1 1 6 
0 5 0 0 0 0 5 
0 5.5 0 1 0 0.5 5 
0 4.5 0 1 0 0.5 4 
1.5 6 0 0 0 0 4 
0 4.5 0 0 0 0 4 
0 3.5 1 0 1 0.5 4 
0.5 5 0 0 0 0 4 
0 3.5 0 0 0 0 3 
0.5 4 0 0 0 0 3 
0 4.5 0 0 0 0 4 
2 4 0 0 0 0 2 
0 4 0 0 0 0 3 
0.5 3.5 0 0 0 0 2 
0 3.5 0 0 0 0 3 
1 5 0 0 0 0 6 
0 4.5 0 1 1 0.5 3 
2 5 1 1 1 1 3 
0.5 5 0 0 0 0 5 
0.5 4 1 1 1 1 3 
0 3.5 0 1 0 0.5 3 
0.5 4.5 0 1 1 0.5 4 
0 3 0 0 0 0 3 
1.5 4.5 0 0 0 0 3 
1.5 5 0 0 0 0 3 
68 
 
0.5 5 0 0 0 0 4 
0 4 0 1 1 0.5 3 
0 4.5 1 1 1 1 4 
0 2.5 0 0 0 0 2 
0 4.5 0 0 0 0 5 
1 6.5 0 1 1 0.5 4 
1.5 5.5 0 1 0 0.5 3 
0 3.5 0 0 0 0 3 
0 2 0 0 0 0 2 
0.5 4.5 0 0 0 0 4 
0.5 4 0 0 0 0 3 
1.5 7 0 1 0 0.5 3 
0 4 1 1 1 1 4 
1.5 5 1 1 1 1 3 




































2 1 1 0 0 3 3 3 
4 0 1 0 0 4 3 3 
4 0 0 1 0 2 4 4 
3 0 1 0 1 3 4 4 
5 2 0 1 1 3 4 4 
4 1 0 0 0 2 4 4 
6 0 0 1 1 3 4 4 
6 0 0 1 0 5 6 6 
3 0 0 1 1 4 3 4 
4 3 0 0 0 2 5 5 
          3 5 5 
5 0 0 1 1 4 5 4 
6 0 0 0 1 5 6 5 
5 2 0 0 0 6 5 6 
4 0 0 1 0 4 4 4 
4 1 1 0 0 3 4 4 
4 0 0 0 0 4 5 4 
3 0 0 0 0 4 3 4 
5 0 1 1 0 4 4 4 
3 0 0 0 0 4 4 4 
4 0 0 0 0 3 4 4 
5 0 0 0 0 4 4 4 
2 2 1 0 0 2 3 2 
4 0 0 0 1 3 5 5 
1 0 0 0 0 3 3 3 
3 0 0 1 1 3 3 3 
7 0 1 0 1 4 4 4 
3 0 0 1 0 5 5 5 
3 1 0 0 1 3 4 4 
5 0 0 0 0 5 5 5 
3 0 0 1 0 3 3 3 
3 0 0 0 1 3 3 3 
5 0 0 0 1 3 3 3 
3 0 1 0 0 3 4 4 
3 1 0 0 0 3 3 3 
3 0 3 0 0 3 3 3 
70 
 
5 0 0 0 0 5 5 5 
3 0 0 0 1 3 4 4 
4 0 0 1 1 4 5 5 
3 0 0 1 0 3 4 4 
4 0 0 0 1 5 4 5 
4 0 1 0 1 5 6 6 
4 0 2 0 1 3 3 3 
4 0 0 0 0 4 4 4 
2 0 0 0 0 3 2 2 
4 0 2 1 0 4 4 4 
5 1 0 1 1 3 4 4 
3 0 0 0 0 7 7 7 
4 0 0 1 1 5 3 5 
3 0 0 0 0 3 3 3 











Site, F rec 
18 
month, 











3 1 1 1 1 4 
3.5 0 0 0 0 3.5 
3 0 0 0 0 3 
3.5 1 2 2 1.5 5 
3.5 0 0 0 0 3.5 
3 0 0 0 0 3 
3.5 0 0 0 0 3.5 
5.5 1 0 0 0.5 6 
3.5 0 0 0 0 3.5 
3.5 4 0 0 2 5.5 
4 0 1 1 0.5 4.5 
4.5 0 0 0 0 4.5 
5.5 0 0 0 0 5.5 
5.5 0 0 0 0 5.5 
4 0 0 0 0 4 
3.5 0 0 0 0 3.5 
4.5 0 0 0 0 4.5 
3.5 0 0 0 0 3.5 
4 1 1 1 1 5 
4 0 0 0 0 4 
3.5 1 0 0 0.5 4 
4 0 0 0 0 4 
2.5 2 2 2 2 4.5 
4 0 0 0 0 4 
3 0 0 0 0 3 
3 0 0 0 0 3 
4 1 0 0 0.5 4.5 
5 0 0 0 0 5 
3.5 0 0 0 0 3.5 
5 0 0 0 0 5 
3 1 0 0 0.5 3.5 
3 0 0 0 0 3 
3 2 2 2 2 5 
3.5 0 0 0 0 3.5 
3 0 0 0 0 3 
3 1 2 1 1.5 4.5 
72 
 
5 0 1 1 0.5 5.5 
3.5 0 0 0 0 3.5 
4.5 0 0 0 0 4.5 
3.5 0 0 0 0 3.5 
4.5 0 0 0 0 4.5 
5.5 0 0 0 0 5.5 
3 1 2 1 1.5 4.5 
4 0 0 0 0 4 
2.5 0 0 0 0 2.5 
4 0 0 0 0 4 
3.5 2 0 0 1 4.5 
7 0 0 0 0 7 
4 1 0 1 0.5 4.5 
3 2 1 1 1.5 4.5 



























1 0 1 0.5 2 4 
1 0 0 0.5 3 4 
1 0 0 0.5 3 4 
0 0 0 0 2 3 
0 0 0 0 3 5 
0 1 1 0.5 2 3 
1 1 1 1 4 5 
0 1 1 0.5 4 6 
1 0 1 0.5 3 3 
0 0 0 0 2 4 
0 0 0 0 5 5 
1 1 1 1 4 4 
0 0 0 0 5 7 
0 0 0 0 4 4 
1 1 1 1 3 2 
1 0 0 0.5 3 4 
0 0 0 0 3 4 
1 1 1 1 4 4 
0 1 1 0.5 3 4 
1 1 1 1 3 3 
0 0 0 0 3 3 
1 0 0 0.5 3 5 
0 0 0 0 3 3 
1 0 0 0.5 3 5 
0 0 0 0 0 0 
0 0 0 0 3 3 
0 0 0 0 3 4 
0 0 0 0 2 2 
0 1 1 0.5 2 3 
0 1 1 0.5 3 3 
1 1 1 1 1 2 
1 0 1 0.5 3 3 
0 0 0 0 2 4 
1 1 1 1 3 4 
0 0 0 0 3 3 
1 0 1 0.5 4 3 
74 
 
1 0 0 0.5 2 3 
1 1 1 1 2 3 
0 0 0 0 2 2 
0 0 0 0 3 3 
1 1 1 1 5 4 
1 1 1 1 4 6 
1 0 1 0.5 3 4 
0 1 1 0.5 3 4 
0 0 0 0 3 3 
0 0 0 0 4 4 
1 1 1 1 2 2 
1 1 1 1 4 3 
1 0 1 0.5 4 4 
0 1 1 0.5 3 3 




























1 1 0 0 4 3 
0 1 0 1 4 4 
1 0 0 0 3 4 
1 2 0 0 3 3 
0 1 1 1 3 4 
3 0 0 0 2 4 
1 0 0 1 5 4 
1 0 0 0 6 6 
1 0 1 0 3 3 
3 0 0 0 2 4 
0 1 1 0 4 5 
0 0 0 0 5 5 
0 0 0 0 4 3 
2 1 1 0 5 5 
0 0 1 1 4 4 
1 1 1 0 3 3 
0 0 0 1 4 4 
0 1 0 1 4 3 
0 0 0 1 4 4 
1 1 0 0 3 3 
1 1 0 0 4 4 
0 0 0 1 3 5 
2 1 1 0 3 3 
0 0 0 0 3 4 
3 3 0 0 3 3 
0 0 0 0 3 3 
1 0 0 0 3 4 
0 0 0 0 4 5 
1 0 0 1 2 5 
3 0 0 0 3 4 
1 0 1 0 3 4 
0 0 0 0 4 5 
2 1 0 0 3 5 
0 0 1 0 2 4 
0 0 0 1 3 3 
1 3 1 1 4 4 
76 
 
0 0 0 1     
0 0 1 0 4 4 
2 1 0 0 3 6 
0 0 0 1 3 4 
0 0 1 1 3 3 
0 1 1 0     
1 2 0 1 3 4 
0 0 0 1     
0 0 0 0 3 3 
0 0 1 0 4 4 
1 1 0 1 3 4 
0 0 0 1 6 7 
1 0 1 0 4 5 
0 0 0 0 2 4 












Site, F rec 
24 month, 








4 3.5 1 1 1 1 
4 4 0 0 0 0 
4 3.5 0 0 0 0 
3 3 1 1 1 1 
4 3.5 0 0 0 0 
4 3 1 0 0 0.5 
4 4.5 0 1 1 0.5 
6 6 2 1 1 1.5 
3 3 0 0 0 0 
4 3 5 1 1 3 
5 4.5 0 0 0 0 
5 5 0 0 0 0 
4 3.5 0 0 0 0 
5 5 0 0 0 0 
4 4 0 1 0 0.5 
3 3 1 1 1 1 
4 4 0 0 0 0 
4 3.5 0 0 0 0 
4 4 1 1 1 1 
3 3 0 0 0 0 
4 4 1 1 1 1 
5 4 0 0 0 0 
3 3 1 2 1 1.5 
4 3.5 0 0 0 0 
3 3 0 0 0 0 
3 3 0 1 0 0.5 
4 3.5 0 0 0 0 
5 4.5 0 0 0 0 
5 3.5 1 1 1 1 
4 3.5 0 0 0 0 
4 3.5 1 0 0 0.5 
4 4.5 0 0 0 0 
5 4 0 0 0 0 
4 3 0 0 0 0 
3 3 0 0 0 0 
4 4 0 0 0 0 
78 
 
          
4 4 0 0 0 0 
6 4.5 0 0 0 0 
4 3.5 0 0 0 0 
3 3 1 0 1 0.5 
          
3 3.5 1 2 1 1.5 
          
3 3 0 0 0 0 
4 4 0 0 0 0 
4 3.5 2 0 0 1 
6 6.5 0 1 0 0.5 
4 4.5 0 0 0 0 
4 3 2 0 0 1 


























4.5 1 1 1 1 2 
4 0 1 1 0.5 4 
3.5 0 0 0 0 1 
4 0 0 0 0 3 
3.5 0 0 0 0 2 
3.5 1 0 0 0.5 2 
5 0 1 1 0.5 2 
7.5 1 0 0 0.5 5 
3 0 0 0 0 2 
6 0 0 0 0 3 
4.5 0 0 0 0 2 
5 0 1 0 0.5 5 
3.5 0 0 0 0 4 
5 0 0 0 0 4 
4.5 0 1 0 0.5 4 
4 0 0 0 0 3 
4 1 0 1 0.5 3 
3.5 1 0 1 0.5 4 
5 0 0 0 0 3 
3 0 0 0 0 3 
5 0 0 0 0 3 
4 0 0 0 0 4 
4.5 0 1 0 0.5 3 
3.5 0 0 0 0 3 
3 0 0 0 0 3 
3.5 0 0 0 0 2 
3.5 0 0 0 0 5 
4.5 0 1 1 0.5 3 
4.5 0 0 0 0 2 
3.5 0 0 0 0 3 
4 1 1 1 1 2 
4.5 1 1 1 1 4 
4 0 0 0 0 4 
3 0 0 0 0 3 
3 1 1 1 1 3 
4 0 0 0 0 3 
80 
 
          
4 1 1 1 1 3 
4.5 1 1 1 1 5 
3.5 1 0 0 0.5 3 
3.5 0 1 0 0.5 3 
          
5 1 1 1 1 3 
          
3 0 0 0 0 3 
4 0 0 0 0 4 
4.5 0 1 0 0.5 2 
7 0 1 0 0.5 3 
4.5 1 1 1 1 3 
4 0 0 0 0 2 










Adj, F rec 
24 
month, 












3 1 1 1 1 3.75 
5 0 0 0 0 3.46 
3 1 0 0 0 2.88 
3 0 1 0 0 3.34 
2 1 0 0 0 1.88 
3 2 0 1 0 1.81 
2 1 1 0 1 3.15 
5 2 0 1 0 3.63 
3 1 0 0 1 3.28 
3 3 1 0 0 5.29 
2 1 1 1 0 1.48 
4 1 0 1 1 3.33 
6 1 0 0 0 4.51 
4 2 0 0 0 4.83 
5 0 0 0 1 2.23 
3 1 1 0 0 4.07 
4 0 0 0 0 2.10 
4 0 0 1 0 3.41 
4 0 0 0 1 3.74 
3 1 0 0 0 2.59 
4 2 1 0 0 2.93 
5 0 0 1 0 3.01 
3 2 1 0 0 3.58 
4 0 0 0 1 2.35 
2 0 0 0 0 6.49 
2 0 1 0 0 5.16 
4 1 0 0 0 4.96 
1 0 0 0 1 3.15 
3 2 1 0 1 5.05 
4 0 0 0 0 4.32 
3 0 0 1 0 4.25 
4 0 0 0 1 3.23 
4 0 0 0 0 4.53 
5 0 0 0 0 1.58 
3 0 0 1 1 5.86 
3 0 0 0 0 5.61 
82 
 
          5.05 
3 0 0 1 1 5.75 
5 0 0 1 1 2.62 
3 0 0 0 0 2.85 
3 0 0 0 1 2.85 
          4.66 
4 2 2 0 0 5.91 
          3.18 
2 0 0 0 0 3.52 
4 1 0 0 0 3.59 
3 2 1 0 1 5.35 
3 0 0 0 0 6.76 
4 0 1 0 1 3.64 
4 0 0 0 0 3.35 























4.02 3.89 3.52 4.37 3.95 3.44 
3.25 3.36 3.21 3.45 3.33 3.12 
3.12 3.00 2.65 2.93 2.79 2.08 
3.79 3.57 3.54 3.78 3.66 3.56 
1.97 1.93 1.74 1.84 1.79 1.63 
1.98 1.90 1.74 2.45 2.10 1.24 
3.25 3.20 2.69 3.77 3.23 2.87 
4.81 4.22 4.21 5.02 4.62 4.45 
3.03 3.16 3.02 3.26 3.14 3.29 
5.63 5.46 5.18 5.47 5.33 5.71 
2.78 2.13 2.20 2.79 2.50 2.26 
4.21 3.77 4.36 4.24 4.30 4.68 
4.67 4.59 4.44 4.68 4.56 4.40 
4.67 4.75 4.62 4.93 4.78 4.60 
2.60 2.42 2.08 2.31 2.20 2.38 
5.61 4.84 3.22 4.80 4.01 3.47 
2.97 2.54 2.21 2.39 2.30 2.47 
2.22 2.82 3.61 2.94 3.28 3.24 
4.84 4.29 3.42 4.26 3.84 3.33 
3.25 2.92 2.39 3.10 2.75 1.72 
3.34 3.14 2.76 3.20 2.98 2.46 
2.77 2.89 2.12 2.80 2.46 1.32 
3.73 3.66 3.18 3.70 3.44 3.39 
2.13 2.24 2.23 1.83 2.03 2.25 
6.62 6.56 6.75 6.49 6.62 6.51 
5.04 5.10      5.14 
5.34 5.15 4.23 4.33 4.28 4.46 
3.87 3.51 2.97 2.74 2.86 3.20 
5.05 5.05 5.15 4.43 4.79 4.98 
3.82 4.07 3.77 3.41 3.59 4.12 
3.29 3.77 3.85 3.26 3.56 4.03 
2.81 3.02 3.31 2.36 2.84 3.48 
4.18 4.36 4.70 4.28 4.49 4.45 
1.92 1.75 1.50 1.75 1.63 1.57 
6.31 6.09 5.16 5.81 5.49 5.35 
5.78 5.70 4.22 2.80 3.51 4.12 
84 
 
  5.05 4.29 2.24 3.27   
3.44 4.60 5.25 3.73 4.49 4.95 
1.76 2.19 2.79 2.16 2.48 2.39 
2.67 2.76 2.74 2.79 2.77 2.66 
2.69 2.77 3.36 3.11 3.24 3.40 
4.12 4.39 4.70 4.20 4.45 3.79 
7.06 6.49 6.06 7.02 6.54 6.82 
2.46 2.82 3.09 2.41 2.75   
3.26 3.39 2.55 2.43 2.49 2.55 
3.77 3.68 4.24 2.82 3.53 3.21 
4.99 5.17 5.18 4.50 4.84 5.34 
6.24 6.50 5.85 6.11 5.98 6.73 
3.36 3.50 3.58 3.35 3.47 3.42 
3.25 3.30 3.08 3.14 3.11 3.17 































































    
 
